Maintenance of Advanced Therapy
| Objective: Appropriate management of patients on advanced therapies during maintenance |
| Patient population: Adult patient (>18 years) with known diagnosis of IBD |
Highlight BoxPatients maintained on advanced IBD therapy should have regular monitoring. |
Introduction
Monitoring may include clinical visits, laboratory tests and/or endoscopy. The results can assist the healthcare team in detecting and minimizing IBD flare.
IBD provider:
1. Document Harvey Bradshaw Index or Partial Mayo score at every visit. Record this value in the patient’s chart. If the patient is flaring, refer to the SUSPECTED IBD OUTPATIENT FLARE protocol. Review information collected during biologic administration, if available. If there are any adverse events or issues, review with the patient. If not, sign and have scanned to the patient chart.
2. Send a message to support staff to make follow-up appointments for 6-12 months and to send out lab requisitions (listed below).
Support Staff:
3. Arrange follow-up clinic visit every 3-6 months (peds) or 6-12 months (adults), after the initial 3-4 months follow-up.
4. Along with the appointment notification, send the patient the following lab requisitions:
- Follow-up (nutritional) bloodwork to be done every 3 – 6 months.
- Fecal Calprotectin kit for the patient to complete every 3 to 6 months or prior to the next appointment. In the pediatric population, FCP should be completed every 6 months for the first year, then annually. Fecal calprotectin can be added to the follow-up requisition if available at the local lab.
5. Ensure that the patient has been scheduled for colonoscopy at 8-12 months or at the provider discretion, as per Induction of Advanced Therapy protocol
IBD Provider:
6. Consider dose optimization if FCP >250 (refer to Loss of Response protocol), but consider the FCP trend
7. Consider dose optimization at 8-12 month colonoscopy or at provider discretion* if not at mucosal healing.
*Flexible sigmoidoscopy for left-sided ulcerative colitis